2014
Impact of Financial Burden of Cancer on Survivors' Quality of Life
Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Impact of Financial Burden of Cancer on Survivors' Quality of Life. JCO Oncology Practice 2014, 10: 332-338. PMID: 24865220, DOI: 10.1200/jop.2013.001322.Peer-Reviewed Original ResearchConceptsQuality of lifeNational Health Interview SurveyStrong independent predictorCancer care costsIndependent predictorsCancer survivorsCare costsHealth Interview SurveyFinancial burdenPopulation-based sampleMultivariable regression modelsMultivariable analysisSurvivors' qualityPatientsBivariate analysisCancerSignificant covariatesMental healthPhysical healthInterview SurveyEmotional healthFinancial problemsSurvivorsPoor qualityRegression models
2012
Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research And Treatment 2012, 137: 631-636. PMID: 23242617, PMCID: PMC3867793, DOI: 10.1007/s10549-012-2374-0.Peer-Reviewed Original ResearchConceptsBreast cancerBone metastasesStage IP1NP levelsSerum levelsIL-6Procollagen type I N-terminal propeptideType I N-terminal propeptideCox proportional hazards regression analysisProportional hazards regression analysisEarly-stage breast cancerPoor OS rateSerum P1NP levelsKaplan-Meier methodOverall survival rateHazards regression analysisLower overall survivalBone metastasis developmentBreast cancer metastasisBlood sample collectionN-terminal propeptideAdvanced diseaseOverall survivalOS ratesSerum P1NP
2004
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: 1337-1342. PMID: 15275718, DOI: 10.1016/j.ijrobp.2004.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibiotics, AntineoplasticBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicConfidence IntervalsDoxorubicinDrug Resistance, NeoplasmFemaleHumansLymphatic MetastasisMastectomy, RadicalNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalRadiation ToleranceReceptor, ErbB-2Receptors, EstrogenRegression AnalysisRetrospective StudiesConceptsHER2/neu-positive diseaseHER2/neu-positive tumorsLocoregional recurrenceHER2/neuNeoadjuvant doxorubicinHER2/neu-negative diseaseHER2/neu-negative tumorsEstrogen receptor-negative diseaseHER2/neu positivityHER2/neu overexpressionChest wall boostNeu-negative tumorsOverall LRR ratePositive lymph nodesReceptor-negative diseaseCox regression analysisEstrogen receptor statusLRR rateSupraclavicular diseaseHazard ratioLymph nodesReceptor statusPostmastectomy radiotherapyPreclinical dataNeu overexpression
2002
Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer
Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, Hortobagyi GN, Pusztai L. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. The Cancer Journal 2002, 8: 461-468. PMID: 12500855, DOI: 10.1097/00130404-200211000-00010.Peer-Reviewed Original ResearchConceptsCore biopsy specimensBiopsy specimensBreast cancerNeoadjuvant chemotherapyGlobal gene expression changesGene expression changesGood pathological responsePrimary breast cancerExpression changesHuman breast cancerHuman solid tumorsPoor respondersPosttreatment specimensPathological responseIndividual patientsChemotherapyPatientsSerial samplesSolid tumorsExpression profilesIndividual tumorsPretreatment samplesDifferent tumorsTumorsDifferent patients